Exendin PET/CT for Imaging of Paragangliomas

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jun 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to see and understand a type of tumor called paraganglioma (PGL). Researchers are testing a special imaging technique that uses a tracer called 68Ga-NODAGA-exendin 4 to help doctors get clearer pictures of these tumors. This method could improve how we look for and evaluate PGLs, which can sometimes be hard to find with existing imaging methods.

To participate in this trial, patients need to have a confirmed diagnosis of a single sympathetic paraganglioma that hasn't spread to other parts of the body. They should also be scheduled for surgery and able to sign consent forms. Unfortunately, individuals who are pregnant, breastfeeding, or have certain kidney issues won't be eligible. If you join the trial, you can expect to undergo the new imaging procedure, which will help researchers learn more about how effective it is in identifying these tumors. This study is currently recruiting participants of all ages, as long as they are 18 or older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Proven sympathetic PGL with a single tumor detected using standard diagnostic imaging
• • No evidence of metastatic disease
• • CT, SSTR PET/CT and 18F-FDG PET/CT performed (golden standard diagnostic imaging)
• • Scheduled for surgery
• • Able to sign informed consent
• Exclusion Criteria:
• • Breast feeding
• • Pregnancy or the wish to become pregnant within 1 month
• • Calculated creatinine clearance below 40ml/min
• • Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions)
• • Age \< 18 years
• • Not able to sign informed consent